Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Decline in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 62,900 shares, a decrease of 52.7% from the November 30th total of 132,900 shares. Based on an average daily trading volume, of 211,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.2% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets cut their price target on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a report on Monday, December 16th.

Alzamend Neuro Trading Down 3.2 %

ALZN stock traded down $0.04 during trading on Friday, hitting $1.20. The stock had a trading volume of 153,815 shares, compared to its average volume of 477,471. Alzamend Neuro has a twelve month low of $1.06 and a twelve month high of $15.06. The company’s 50-day moving average price is $1.37 and its two-hundred day moving average price is $2.37.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.